Determination of Total and Free Plasma Concentration of Liposomal Mitoxantrone and Clinical Application in Adult Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s542030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Yuxiang Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China. Hauptthemen laut MEDLINE: Mitoxantrone, Antineoplastic Agents, Lymphoma, T-Cell, Peripheral. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China.
ORCID-Profile: Yuxiang Xu, Xiaonan Gao, Jinglin Gao, Zhangying Feng
Zitieren
APA
Xu, Y., Zhang, Q., Qie, H., Gao, X., Gao, J., Feng, Z., & Wang, M. (2025). Determination of Total and Free Plasma Concentration of Liposomal Mitoxantrone and Clinical Application in Adult Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s542030
Vancouver
Xu Y, Zhang Q, Qie H, Gao X, Gao J, Feng Z, et al. Determination of Total and Free Plasma Concentration of Liposomal Mitoxantrone and Clinical Application in Adult Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s542030
BibTeX
@article{Xu2025,
author = {Xu, Yuxiang and Zhang, Qi and Qie, Hongxin and Gao, Xiaonan and Gao, Jinglin and Feng, Zhangying and Wang, Mingxia},
title = {Determination of Total and Free Plasma Concentration of Liposomal Mitoxantrone and Clinical Application in Adult Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s542030}
}
EUVIMED